OMB APPROVAL
OMB Number: 3235-0145
Expires: October 31, 1994
Estimated average burden
hours per response...14.90
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Microcide Pharmaceuticals, Inc.
-------------------------------
(Name of Issuer)
Common Stock, no par value
-------------------------------
(Title of Class of Securities)
59501810
--------------
(CUSIP Number)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
Item 1(a). Name of Issuer: Microcide Pharmaceuticals, Inc.
Item 1(b). Address of Issuer's Principal Executive Offices:
850 Maude Avenue, Mountain View, CA 94043.
Item 2(a). Names of Persons Filing: Frank A. Bonsal, Jr.
Item 2(b). Address of Principal Business Office or, if None, Residence:
The address of the principal business office of Mr. Bonsal is New
Enterprise Associates, 1119 St. Paul Street, Baltimore, Maryland
21202.
Item 5. Ownership of Five Percent or Less of a Class.
Mr. Bonsal has ceased to own beneficially more than 5% of the
outstanding Common Stock of Microcide Pharmaceuticals, Inc.
All other items reported on the Schedule 13G dated as of February 10, 1997 and
filed on behalf of Mr. Bonsal and others with respect to the Common Stock of
Microcide Pharmaceuticals, Inc.
remain unchanged.
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of its knowledge and belief, each
of the undersigned certifies that the information set forth in this statement is
true, complete and correct.
Date: February 10, 1998
*
- ----------------------------------
Frank A. Bonsal, Jr.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
<PAGE>
*By: /s/ Nancy L. Dorman
-----------------------------------------
Nancy L. Dorman, in her individual
capacity and as Attorney-in-Fact
- -------------------------------------------------------------------------------
This Schedule 13G was executed by Nancy L. Dorman pursuant to Powers of Attorney
filed with the Securities and Exchange Commission on February 13, 1992 in
connection with a Schedule 13G for Advanced Interventional Systems Inc. and on
February 13, 1995 in connection with a Schedule 13G for Acuity Imaging, Inc.,
which Powers of Attorney are incorporated herein by reference.
